This article is from the source 'bbc' and was first published or seen on . It will not be checked again for changes.

You can find the current article at its original source at http://news.bbc.co.uk/go/rss/-/1/hi/scotland/tayside_and_central/6763409.stm

The article has changed 2 times. There is an RSS feed of changes available.

Version 0 Version 1
Gene defect find in asthma study Gene defect find in asthma study
(about 3 hours later)
Scientists in Dundee carrying out research into asthma believe they have made a breakthrough which could alter the treatment of the condition.Scientists in Dundee carrying out research into asthma believe they have made a breakthrough which could alter the treatment of the condition.
The University of Dundee team announced last year that they had identified the gene producing the protein filaggrin which causes asthma and eczema.The University of Dundee team announced last year that they had identified the gene producing the protein filaggrin which causes asthma and eczema.
Through continuing research, they have now discovered that defects in the same gene could affect treatment.Through continuing research, they have now discovered that defects in the same gene could affect treatment.
This, they said, could lead to a big reduction in medication requirements.This, they said, could lead to a big reduction in medication requirements.
The protein filaggrin is normally found in large quantities in the outermost layers of the skin - essentially keeping water in and foreign organisms out.The protein filaggrin is normally found in large quantities in the outermost layers of the skin - essentially keeping water in and foreign organisms out.
Our findings show that these gene defects that affect the skin barrier which filaggrin provides has a significant effect on day-to-day asthma morbidity and medication we use Dr Somnath MukhopadhyayOur findings show that these gene defects that affect the skin barrier which filaggrin provides has a significant effect on day-to-day asthma morbidity and medication we use Dr Somnath Mukhopadhyay
The latest discovery of defects in the gene has led the scientists, Dr Somnath Mukhopadhyay, Dr Colin Palmer and Professor Irwin McLean, to identify how it can determine the amount of treatment that a child or young adult with asthma needs on a day-to-day basis.The latest discovery of defects in the gene has led the scientists, Dr Somnath Mukhopadhyay, Dr Colin Palmer and Professor Irwin McLean, to identify how it can determine the amount of treatment that a child or young adult with asthma needs on a day-to-day basis.
In a new paper published in The Journal of Allergy and Clinical Immunology, the team show the defects in the gene can make asthma patients three to six times more likely to have to reach out for their inhaler every day.In a new paper published in The Journal of Allergy and Clinical Immunology, the team show the defects in the gene can make asthma patients three to six times more likely to have to reach out for their inhaler every day.
These patients are more likely to need extra medicines on top of inhaled steroids to control their asthma.These patients are more likely to need extra medicines on top of inhaled steroids to control their asthma.
'Reduce medication''Reduce medication'
Dr Mukhopadhyay said: "Our findings show that these gene defects that affect the skin barrier which filaggrin provides has a significant effect on day-to-day asthma morbidity and medication we use.Dr Mukhopadhyay said: "Our findings show that these gene defects that affect the skin barrier which filaggrin provides has a significant effect on day-to-day asthma morbidity and medication we use.
"If these genetic skin barrier defects directly exacerbate asthma, young asthma sufferers who show these barrier defects may respond better to allergen withdrawal strategies."If these genetic skin barrier defects directly exacerbate asthma, young asthma sufferers who show these barrier defects may respond better to allergen withdrawal strategies.
"This would lead to a significant long-term reduction in asthma medication requirements.""This would lead to a significant long-term reduction in asthma medication requirements."
The research was carried out on child asthma sufferers in Tayside with support from GPs in Dundee, Perth and Kinross, Angus and Fife.The research was carried out on child asthma sufferers in Tayside with support from GPs in Dundee, Perth and Kinross, Angus and Fife.
Scotland has one of the highest rates of children's asthma in the world.